Evidence map›Paper›PMID 42272358›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Biochemical Structure Evolved Pyridine-Activated Carbon Dots Co-Assembly as Precision Antitumor Nanozyme.

Lingyun Li, Xue Wu, Zhenjian Li, Xianming Zhang, Yingqi Liang, Zekun Yan, Yupeng Liu, Caishi Huang, Songnan Qu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lingyun LiInstitute of Applied Physics and Materials Engineering, Joint Key Laboratory of the Ministry of Education, University of Macau, Taipa, Macau SAR, P. R. China.
Xue WuInstitute of Applied Physics and Materials Engineering, Joint Key Laboratory of the Ministry of Education, University of Macau, Taipa, Macau SAR, P. R. China.
Zhenjian LiInstitute of Applied Physics and Materials Engineering, Joint Key Laboratory of the Ministry of Education, University of Macau, Taipa, Macau SAR, P. R. China.
Xianming ZhangInstitute of Applied Physics and Materials Engineering, Joint Key Laboratory of the Ministry of Education, University of Macau, Taipa, Macau SAR, P. R. China.
Yingqi LiangInstitute of Applied Physics and Materials Engineering, Joint Key Laboratory of the Ministry of Education, University of Macau, Taipa, Macau SAR, P. R. China.
Zekun YanInstitute of Applied Physics and Materials Engineering, Joint Key Laboratory of the Ministry of Education, University of Macau, Taipa, Macau SAR, P. R. China.
Yupeng LiuInstitute of Applied Physics and Materials Engineering, Joint Key Laboratory of the Ministry of Education, University of Macau, Taipa, Macau SAR, P. R. China.
Caishi HuangFaculty of Health Science, University of Macau, Taipa, Macau SAR, P. R. China.
Songnan QuInstitute of Applied Physics and Materials Engineering, Joint Key Laboratory of the Ministry of Education, University of Macau, Taipa, Macau SAR, P. R. China.ORCID 0000-0003-4159-096X

Funding

Science and Technology Development Fund of Macau SAR 0002/2024/TFPScience and Technology Development Fund of Macau SAR 0005/2024/AKPScience and Technology Development Fund of Macau SAR 0139/2022/A3Science and Technology Development Fund of Macau SAR MYRG-CRG2025-00011-FHSScience and Technology Development Fund of Macau SAR MYRG-GRG2025-00148-IAPMEUniversity of Macau
6 · The paper itself

Abstract

Nanozymes with stable activity and excellent biocompatibility hold significant potential for tumor catalytic therapy. However, lacking rational structure evolution strategies to enhance nanozyme biochemical activity and their almost non-tumor specificity have hindered their clinical translation. In this study, we report a pyridine-activated donor-acceptor (D-A)-typed carbon dots (N-CDs), and their co-assembled nanoplatform (N-CDs@KK) with a programmed death-ligand 1 (PD-L1) targeting peptide (KK), as a potent tumor-targeted nanozyme. N-CDs were engineered through structure evolution via homogeneously integrating electron-withdrawing pyridine units into amino-rich conjugated sp

Indexed as

Antineoplastic AgentsCarbon Quantum DotsPyridinesAnimalsB7-H1 AntigenCarbonCatalysisCell Line, TumorCell ProliferationHumansReactive Oxygen SpeciesAntineoplastic AgentsB7-H1 AntigenCarbonpyridinePyridinesReactive Oxygen Speciescarbon quantum dotsimmune checkpoint inhibitorsoxidative stresstumor therapy

Identifiers

PMID42272358
PMCPMC13452487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.